| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2007, p. 1840-1843, Vol. 51, No. 5
0066-4804/07/$08.00+0 doi:10.1128/AAC.01283-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Infectious Diseases,1 Department of Clinical Microbiology,2 Örebro University Hospital, Örebro, Department of Clinical Sciences, Malmö, Lund University, Lund,3 Swedish Institute for Infectious Disease Control, Solna, Sweden4
Received 13 October 2006/ Returned for modification 10 November 2006/ Accepted 2 February 2007
In silico, we identified fusA (2,067 bp) in Clostridium difficile 630. Sequencing of fusA in posttherapy fusidic acid-resistant C. difficile isolates from 12 patients with C. difficile-associated diarrhea (CDAD) identified fusA mutations, one or two nonsynonymous substitutions, or in one case a deletion of one codon associated with resistance. Five of these mutations have previously been described in fusA of fusidic acid-resistant Staphylococcus aureus, but seven were novel fusA mutations. Fusidic acid monotherapy for CDAD seemed to rapidly select conserved resistant mutants.
Published ahead of print on 16 February 2007.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |